NCT01685073
The Role of Sleep in the Treatment of Cannabis Use Disorders
See it on ClinicalTrials.gov ↗127 people
37.8%
62.2%
48 womenmiddle line = equal numbers79 men
- Phase
- PHASE2, PHASE3
- Paid for by
- Johns Hopkins University
- Finished
- 2018-07
- Health conditions
- Drug Addiction
- Who could join
- Anyone
- Ages
- 18 Years – 55 Years
- Average age
- mean 31 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 55 Years.”
- No pregnant women
Women who were pregnant could not join.
“Pregnant, breast feeding, or planning to become pregnant within the next 3 months”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant, breast feeding, or planning to become pregnant within the next 3 months”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Current use of drugs that affect metabolism via cytochrome P450 or current illness resulting in severe hepatic impairment”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Dependent on drugs other than cannabis or nicotine, or current Axis I psychiatric disorder”
- No smokers
Women who smoke or use nicotine were turned away.
“Dependent on drugs other than cannabis or nicotine, or current Axis I psychiatric disorder”
Study titles and rules are shown in their original English.